Home ▸ News

Ischemix Appoints Clinical Trial Liaison

March 24, 2015

Ischemix announced today the appointment of Patricia Baum as Clinical Trial Liaison. Ms. Baum was previously Cardiology Research Coordinator at the Lahey Clinic Medical Center in Burlington, MA.

"We are very pleased to welcome Ms. Baum to fill this newly created role within the Company. Her very strong background in clinical trial management, combined with her specific expertise in conducting clinical trials in the cardiac catheterization lab makes her an ideal addition to our team" said David DeWahl, President and CEO of the Company. He added "Patricia will work very closely with the clinical trial sites participating in our 240-subject CARIN trial, which is studying the ability of our lead compound, CMX-2043, to reduce the incidence of contrast-induced acute kidney injury ("CI-AKI") and peri-procedural MI in patients entering the cardiac catheterization lab."

Ms. Baum previously worked for Abiomed as Clinical Director, and at Biogen Idec, Brigham and Women's Hospital and the Cleveland Clinic. She received her BS in Nursing cum laude from Ursuline College. Ms. Baum was co-founder, first journal editor and president of the Society for Vascular Nursing. She is the author or co-author of numerous peer-reviewed journal articles.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing a portfolio of novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. Cytoprotective compounds have broad potential therapeutic utility in multiple organ systems and disease states. The Company's lead product candidate, CMX-2043, is a patented, new chemical entity based on a naturally-occurring compound.

Ischemix has previously released positive data from SUPPORT-1, a 140-patient Phase 2a of CMX-2043, which demonstrated the ability of the compound to reduce the rise in biomarkers of cell death to a statistically significant degree in subjects undergoing PCI. Ischemix is currently enrolling subjects in a 240-patient CARIN trail to study the ability of CMX-2043 to reduce the incidence of contrast-induced acute kidney injury ("CI-AKI") and peri-procedural MI in patients entering the cardiac catheterization lab. The Company is also engaged in studying the use of CMX-2043 and other compounds for additional indications.

Latest News

August, 2023

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

July 7, 2021

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

March 25, 2019

Novel Compound for Treatment of Traumatic Brain Injury (TBI) Demonstrates Positive Results in a Preclinical Study

April 4, 2016

Ischemix Announces Results of Its Phase 2 CARIN Trial

January 5, 2016

Ischemix, Inc. to Present at Biotech Showcase™ on January 13, 2016

December 9, 2015

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

September 30, 2015

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

August 12, 2015

Ischemix Elects Peter G. Milner, MD to Board of Directors

May 19, 2015

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

March 24, 2015

Ischemix Appoints Clinical Trial Liaison

June 26, 2014

Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Inury

January 9, 2013

Ischemix Appoints new Chief Executive Officer

June 17, 2011

Ischemix Completes Phase 2a Clinical Trial

March 2, 2011

Ischemix Granted Composition of Matter Patent for CMX-2043

March 9, 2010

Ischemix Initiates Phase 2a Clinical Trial

August 13, 2007

Ischemix Completes Phase 1 Clinical Trial

April 5, 2007

Ischemix Initiates Clinical Development